At $16, Hims & Hers Health stock is cheap on sales metrics, but upside is capped pending regulatory clarity and proof of ...

Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter for the “Carillon ...

Heightened regulatory scrutiny could be a major blow for the online drug retailer, which just shelved its plan for a Wegovy ...

Hims & Hers Health launched a compounded semaglutide based weight loss pill, then quickly pulled it following legal threats from Novo Nordisk and federal scrutiny. Federal regulators have referred the ...

Recent discussions on X about Hims & Hers Health (HIMS) have been buzzing with interest, particularly around the company's innovative telehealth model and its rapid revenue growth. Many users have ...

Hims & Hers is rated Hold as regulatory/legal risks hit its GLP-1 weight-loss pivot; resilient core & strong liquidity noted. Click to read more on HIMS stock.

Presented by the Coalition to Strengthen America’s Healthcare{beacon} Health Care Health Care The Big Story Legal pressures ...

Virtual healthcare platforms are redefining patient access to care, with Hims & Hers Health, Inc. HIMS and GoodRx Holdings, Inc. GDRX among the leaders in this digital shift. HIMS is a consumer-first, ...

This release is an informational overview of publicly available disclosures for Hims GLP-1 Weight Loss and broader consumer ...

It has been about a month since the last earnings report for Hims & Hers Health, Inc. (HIMS). Shares have lost about 15.1% in that time frame, underperforming the S&P 500. Will the recent negative ...